Anteris Technologies Global Corp. — Capital/Financing Update 2021

May 23, 2021

ASX ANNOUNCEMENT

24 May 2021

CAPITAL RAISING

Brisbane, Australia and Minneapolis USA.

Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) announces placing 310,386 new Ordinary Shares to predominantly existing Top 10 institutional shareholders at $7.50 each for a total $2.3 million. Funds are for additional working capital.

Additionally, the placement investors will receive one unlisted 2-year Option exercisable at $11.50 for every two new Shares issued (totaling 155,200 Options and subject to shareholder approval). If shareholder approval is not granted, investors will instead receive a cash payment equivalent to $1.25 per Option.

The new Share placement was covered by the Company’s available placement capacity under Listing Rule 7.1. The placement price was fixed at a 9% discount to the 5-day VWAP.

Evolution Capital Advisors Pty Ltd will be paid a fee for facilitating the Placement of $81,739 and will receive 50,000 Options (also subject to shareholder approval). The Options will be unlisted 2- year Options exercisable at $11.50. If shareholder approval to issue the Options is not granted, Evolution will instead receive a cash payment of $62,500 (being $1.25 per Option).

Shareholder approval to issue the Options to Placement investors and Evolution Capital Advisors Pty Ltd will be sought at the Company’s annual general meeting to be held in July 2021.

ENDS About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT[®] tissue technology, paired with DurAVR™’s unique 3D singlepiece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Anteris Technologies Ltd Registered Office:

==> picture [95 x 51] intentionally omitted <==

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Ms Kyahn Williamson WE Communications E: WE-AUAnterisTech@we-worldwide.com P: +61 401 018 828 www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

==> picture [95 x 52] intentionally omitted <==